Jump to Main Content


Ruxience Approved Treatment Adult Patients Non-Hodgkin Lymphoma

The U.S. Food and Drug Administration (FDA) approved Ruxience (rituximab-pvvr), a biosimilar to U.S.-licensed Rituxan (rituximab) for the treatment of adult patients with CD20-positive B-cell non-Hodgkin lymphoma (NHL) to be used as a single agent or in combination with chemotherapy, and CD20-positive Chronic Lymphocytic Leukemia (CLL) in combination with chemotherapy.